Melbourne, Australia, 13 March 2018: Sienna Cancer Diagnostics Ltd (ASX:SDX), a commercial stage, medical technology company focused on the development and commercialisation of innovative cancer- related tests is pleased to announce the first sale of the company’s hTERT test in Switzerland through its distribution partner, Biosystems Switzerland AG.
Following the signing of Biosystems Switzerland as the exclusive distributor for Switzerland of Sienna’s novel IVD test, the first order by a Swiss laboratory has been delivered. This follows training of Biosystems key personnel by Sienna in late 2017, and evaluation and clinical validation by the customer.
For further information please download PDF attached:
Download this document
